Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Center-specific Federated Learning for Radiation Pneumonitis:A Cross-Center Adaptive Alternating Framework.

International journal of radiation oncology, biology, physics·2026
Same author

Artificial Intelligence and the Global Radiotherapy Gap.

JCO global oncology·2026
Same author

Disaggregating Gender Inequality Globally: Health Systems, Gender Inequality, and Female Pan-Cancer Outcomes.

JCO global oncology·2026
Same author

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

NPJ precision oncology·2026
Same author

Wearable-Derived Data for Patient Frailty: Extending Hospital Frailty Risk Score While Confronting Bias and Inequities.

Journal of general internal medicine·2026
Same author

Beyond auto-segmentation: the case for planning and dosimetry AI in head and neck radiation oncology.

BMJ oncology·2026

Related Experiment Video

Updated: May 7, 2026

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

9.5K

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Jonas Willmann1,2, Edward Christopher Dee3, Lizza E L Hendriks4

  • 1Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 5, 2026
PubMed
Summary

Metastatic trajectories offer a new framework for understanding intrapatient heterogeneity in metastatic non-small cell lung cancer (NSCLC). This approach tracks individual lesion behavior over time to guide adaptive, precision treatment strategies.

More Related Videos

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

43.7K
Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.7K

Related Experiment Videos

Last Updated: May 7, 2026

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

9.5K
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

43.7K
Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.7K

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Systemic therapies have improved outcomes for metastatic non-small cell lung cancer (NSCLC), but resistance and progression are common.
  • Current classifications do not capture lesion-level heterogeneity, limiting adaptive treatment strategies.

Purpose of the Study:

  • Introduce the concept of "metastatic trajectories" to characterize intrapatient heterogeneity.
  • Provide a framework for informing adaptive treatment strategies in metastatic NSCLC.
  • Shift focus from overall disease states to individual lesion behavior over time.

Main Methods:

  • Define dimensions of metastatic trajectories (response, resistance, organotropism, progression patterns).
  • Review biological foundations of intrapatient heterogeneity (genomic diversification, plasticity, tumor microenvironment).
  • Discuss emerging biomarkers (ctDNA, radiomics) and imaging for tracking trajectory evolution.

Main Results:

  • Metastatic trajectories enable reactive and anticipatory treatment strategies.
  • Understanding lesion-level dynamics can refine patient selection for local and systemic therapies.
  • Proposed standardized parameters facilitate consistent documentation and validation.

Conclusions:

  • Integrating trajectory-based assessment into clinical practice can enable biology-informed treatment adaptation.
  • This framework supports next-generation clinical trials for precision management of metastatic NSCLC.
  • Metastatic trajectories offer a novel approach to managing complex metastatic disease.